PPT-Switch to LPV/r + RAL

Switch to LPVr RAL KITE Study KITE Study switch to LPVr RAL Design Age 18 years HIV No previous virologi c failure to PIrbased ART HIV1 RNA lt 50 cml On stable 6 months 2 NRTI 3rd agent. of HIV Infection. Dual therapies without NRTIs. Jean-Guy Baril, MD. Clinique médicale du Quartier Latin. CHUM. This activity is supported by. an educational grant from:. Received consultant, investigator or speaker honoraria/grants from the following companies . RAL RGB (approx.) HEX (approx.) English RAL 1000 214-199-148 #BEBD7F Green beige RAL 1001 217-186-140 #C2B078 Beige RAL 1002 198-166-100 #C6A664 Sand yellow RAL 1003 229-190-001 #E5BE01 RAL 1004 205-1 for . treatment monitoring. Nathan . Ford. Dept. of . HIV/AIDS. World Health . Organization. WHO ART guidelines evolution. Topic. 2002. 2003. 2006. 2010. 2013. When to start. CD4 ≤200. CD4 ≤ 200. A . major new European . particle physics project. Fergus. Wilson, RAL/STFC. On. behalf of the SuperB Project. Beauty 2011, April 8. th. 2011. Outline. Unique Selling Points (. USPs. ). Snapshot of SuperB . QDMRK. SPRING-2. ONCEMRK. ONCEMRK. Design. Objective. Non inferiority of RAL QD: % HIV RNA < 40 c/mL by ITT, NC=F . (lower margin of the 2-sided 95% CI for the difference = - 10%, 90% power). RAL 1200 mg ** QD + . Benjamin B. . Bederson. www.cs.umd.edu/~bederson. @. bederson. Computer Science Department. Human-Computer Interaction Lab. Institute for Advanced Computer Studies. iSchool. University of Maryland. Programmer. Tim Stanley, . MICE RF Engineer, RAL. 2 June 2014. RF Amplifiers – Performance at DL. RF Amplifiers - Performance. 2 MW RF output was achieved at . Daresbury. , in July 2013, on amplifier chain #1.. M. edications. in . Paediatrics. Dr Leon J. Levin. Head - . Paediatric. HIV . Programmes. Right to Care. New Regimens for DOH and Private Sector in SA.  . 0-3 years. >3years and >10 kg.  . 1. Switch to LPV/r + RAL KITE Study KITE Study: switch to LPV/r + RAL Design Age ≥ 18 years HIV+ No previous virologi c failure to PI/r-based ART HIV-1 RNA < 50 c/ml On stable (≥ 6 months) 2 NRTI + 3rd agent 2020-02 nd. 90: Child Friendly Formulations . Victor Musiime, . MBChB. , MMED, PhD. Senior Lecturer, . Makerere. University. Investigator, Joint Clinical Research Centre. Kampala, Uganda. Disclosure statement. by Baseline NRTI Resistance . and Second-Line NRTI Use. Dannae. Brown,. 1. . Ruolan. Wang,. 2. Mark Underwood,. 2. Judy Hopking,. 3. Maria Claudia Nascimento,. 4. . Michael Aboud,. 4. . Jörg. Canadian Study. CHEER. Montreal Study. EASIER. SWITCHMRK. SPIRAL. Switch ER. Design. Endpoints. Primary: non inferiority in the proportion of patients with treatment failure at W48* (non completer = failure, intent-to-treat analysis), lower . HIV-NAT . 017. SQV and . LPV-RTV . in Treatment-Experienced Children . HIV-NAT . 017: . Study . Design. Source: . Kosalaraksa. P, et al. . Pediatr. Infect Dis J. . 2008;27:. 623-8. . SQV + LPV-RTV +/- 3TC.